A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease

Journal of Inherited Metabolic Disease

Volumn 38, Issue 6, 2015, Pages 1129-1136

  Schiffmann, Raphael ^a   Swift, Caren ^a   Wang, Xuan ^b   Blankenship, Derek ^b   Ries, Markus ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ENZYME ANTIBODY; GLOBOTRIAOSYLCERAMIDE; ALPHA GALACTOSIDASE; CERAMIDE TRIHEXOSIDE; ISOENZYME;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; ENZYME REPLACEMENT; FABRY DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; INFUSION RELATED REACTION; KIDNEY FUNCTION; MIDDLE AGED; OPEN STUDY; PERSONALIZED MEDICINE; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT DURATION; URINARY EXCRETION; URINE LEVEL; YOUNG ADULT; BLOOD; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; STATISTICAL MODEL; UNITED STATES; URINE;

ADULT; ALPHA-GALACTOSIDASE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; ISOENZYMES; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIHEXOSYLCERAMIDES; UNITED STATES; YOUNG ADULT;

EID: 84945443992     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-015-9845-5     Document Type: Article

References (34)

1. Altarescu G, Schiffmann R, Parker CC et al (2000) Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 26:285–290
2. Anderson LJ, Wyatt KM, Henley W et al (2014) Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 27(6):969–978. doi:10.1007/s10545-014-9717-4
3. Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard Lund A (2013) Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet 83:432–438
4. Brady RO, Schiffmann R (2000) Clinical features of and recent advances in therapy for Fabry disease. JAMA 284:2771–2775
5. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167
6. Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal Disease: influence of alpha- galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138
7. Coresh J, Turin TC, Matsushita K et al (2014) Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311:2518–2531
8. El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2, CD006663
9. EMA Fabrazyme: EPAR - Product Information In Editor ed.^eds. Book Fabrazyme: EPAR - Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000370/WC500020547.pdf. Accessed 27 July 2014
10. EMA Replagal: EPAR - Product Information. In Editor ed.^eds. Book Replagal: EPAR - Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000369/WC500053612.pdf. Accessed 24 July 2014
11. Eng CM, Banikazemi M, Gordon RE et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722
12. FDA FABRAZYME, BLA no. 103979 In Editor ed.^eds. Book FABRAZYME, BLA no. 103979. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103979s5135lbl.pdf. Accessed 24 July 2014
13. Hughes DA, Deegan PB, Milligan A et al (2013) A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease. Mol Genet Metab 109:269–275
14. Levey AS (2002) Clinical practice. Nondiabetic kidney disease. N Engl J Med 347:1505–1511
15. Lin HY, Huang YH, Liao HC et al (2014) Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa. J Chin Med Assoc 77:190–197
16. Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465–473
17. Pisani A, Spinelli L, Visciano B et al (2013) Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. JIMD Rep 9:41–48
18. Ries M, Ramaswami U, Parini R et al (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162:767–772
19. Ries M, Gupta S, Moore DF et al (2005) Pediatric Fabry disease. Pediatrics 115:e344–e355
20. Ries M, Kim HJ, Zalewski CK et al (2007) Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 130:143–150
21. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 37:341–352
22. Schiffmann R, Murray GJ, Treco D et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97:365–370
23. Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 285:2743–2749
24. Schiffmann R, Floeter MK, Dambrosia JM et al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710
25. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345–354
26. Schiffmann R, Askari H, Timmons M et al (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18:1576–1583
27. Schiffmann R, Ries M, Blankenship D et al (2013) Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genet Med 15:983–989
28. Sirrs SM, Bichet DG, Casey R et al (2014) Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 111:499–506
29. Tondel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol: JASN 24:137–148
30. Tsuboi K, Yamamoto H (2014) Clinical course of patients with Fabry disease who were switched from agalsidase-beta to agalsidase-alpha. Genet Med 16:766–772
31. van der Tol L, Smid BE, Poorthuis BJ et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1–9
32. Weidemann F, Niemann M, Stork S et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331–341
33. Weidemann F, Kramer J, Duning T et al (2014) Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol 25:837–849
34. Wraith JE, Tylki-Szymanska A, Guffon N et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152:563–570, 570 e561